Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

priority access

- PMLiVE

AstraZeneca and MSD report final overall survival results from prostate cancer study

The combination treatment increased the current patient survival rate by over seven months

- PMLiVE

Janssen reports updated phase 3 results for niraparib combination in prostate cancer

Prostate cancer is the most common cancer affecting men in Europe

- PMLiVE

AstraZeneca’s Evusheld not recommended by NICE for COVID-19 prevention

The agency said there is not enough evidence of the drug’s effectiveness against current variants

- PMLiVE

AstraZeneca progresses application for $360m Ireland manufacturing site

The investment is expected to create around 100 highly skilled jobs

Case study: How we iteratively tested and refined payer value messages

Find out how we helped our client to enrich their understanding of the value message trade-off choices and preferences made by payers

Research Partnership

- PMLiVE

AstraZeneca’s heart failure treatment approved for expanded use in EU

Chronic heart failure is the leading cause of hospitalisation for those over the age of 65

- PMLiVE

Novartis’ Cosentyx shows continued improvement in hidradenitis suppurativa patients

An estimated one in 100 people globally are affected by the inflammatory skin disease

- PMLiVE

AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer

Around 210,000 people worldwide are diagnosed with the disease each year

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer

Breast cancer is one of the leading causes of cancer-related deaths globally, with more than two millions cases diagnosed in 2020

- PMLiVE

AstraZeneca joins UK pilot evaluating AI-based lung cancer diagnosis system

More than 43,000 people are diagnosed with lung cancer every year in the UK

- PMLiVE

AstraZeneca’s severe asthma treatment approved in EU for self-administration

Most healthcare providers, patients and caregivers are able to successfully use the pre-filled pen

- PMLiVE

AstraZeneca and Avillion’s asthma rescue treatment granted FDA approval

Airsupra significantly reduces the risk of severe asthma exacerbations

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links